Table 3.
Outcome | Total Sample % | Control % | Intervention % | Exp(B) | 95% C.I. |
---|---|---|---|---|---|
Verified visit to discuss prostate cancer with physician | 12.1 | 8.3 | 15.8 | 2.127*** | 1.152 – 3.925 |
Plan to test for prostate cancer pretest | 60.2 | 59.3 | 61.1 | 1.076 | .748 – 1.548 |
Plan to test for prostate cancer posttest | 81.0 | 81.0 | 80.9 | .994 | .614 – 1.610 |
Testing benefits outweigh risks posttest | 30.9 | 28.2 | 33.5 | 1.283 | .848 – 1.942 |
Verified PSA 1-year follow-up | 45.5 | 45.9 | 45.1 | .965 | .671 – 1.386 |
Verified PSA 2-year follow-up | 64.7 | 66.7 | 62.7 | .829 | .564 – 1.218 |
Congruence between intention to test and verified PSA test 1-year follow-up | 56.7 | 58.1 | 55.3 | .891 | .621 – 1.279 |
Congruence between intention to test and verified PSA test 2-year follow-up | 59.2 | 59.3 | 59.0 | .986 | .686 – 1.417 |
Notes.
For all self-report data, the pre-test sample size was 490 (246 control group; 244 experimental group), whereas the post-test sample size was 431 (216 control group; 215 experimental group). However, the sample size was 490 (246 control group; 244 experimental group) for data using medical claims records.
All analyses adjusted for the covariates education level and claims-verified PSA test prior to pretest.
p<.05
p<.01
p<.001